Reunion Neuroscience Inc. REUN.TO
Quote time unavailable
Day range unavailable
52-week range unavailable
- Market cap
- 16.99M
- Shares out
- 11.72M
- Forward P/E
- -0.90
- Beta
- 4.21
Key statistics
- Enterprise value
- -9.98M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -7.05M
- Total cash
- 27.20M
- Total debt
- 0
- Return on equity
- -86.35%
- Short % of float
- 0.00%
- 50-day average
- 1.25
- 200-day average
- 1.55
About Reunion Neuroscience Inc.
Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- reunionneuro.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on REUN.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Fishman (Barry) | Director of Issuer | Stock split or consolidation | Aug 10, 2022 | 30,000 |
| Fleiman (Hannan) | Director of Issuer | Stock split or consolidation | Aug 10, 2022 | 0 |
| Hewitt (Paula Amy) | Senior Officer of Issuer | Stock split or consolidation | Aug 10, 2022 | 769 |
| Jafferi (Mujeeb) | Director of Issuer | Stock split or consolidation | Aug 10, 2022 | 724,516 |
| Levy (Ronan) | Director of Issuer | Stock split or consolidation | Aug 10, 2022 | 0 |
| Lubman (Ellen) | Director of Issuer | Stock split or consolidation | Aug 10, 2022 | 40 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Oasis Management Co Ltd. | 3.99% | 467,435 | 677.78K | Mar 30, 2023 |
| AdvisorShares Investments, LLC | 2.92% | 342,529 | 496.67K | Mar 30, 2023 |
| Avidity Partners Management, LP | 1.29% | 151,098 | 219.09K | Mar 30, 2023 |
| One + One Wealth Management, LLC | 0.65% | 76,000 | 110.20K | Mar 30, 2023 |
| Vivaldi Capital Management Lp | 0.26% | 30,000 | 43.50K | Mar 30, 2023 |
| Jane Street Group, LLC | 0.19% | 22,757 | 33.00K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 2.92% | 342,529 | 496.67K | Mar 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 925 | 1.34K | Feb 27, 2023 |
